Skip to main navigation Skip to search Skip to main content

Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin

Yaojun Peng, Li Wang, Liangliang Wu, Ling Zhang, Guangjun Nie, Mingzhou Guo

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aim: Human SLFN11 gene encodes a protein with structural similarity to RNA helicases, which was reported to sensitize cancer cells to DNA-damaging agents. This study explored the epigenetic regulation and mechanism of SLFN11 in human gastric cancer. Methods: Eight human gastric cancer cell lines and 201 cases of primary gastric cancer were analyzed. Methylation specific PCR, flow cytometry, xenograft mouse model and siRNA technique were employed. Results: SLFN11 was methylated in 29.9% (60/201) of primary gastric cancer. The expression of SLFN11 was regulated by promoter region methylation. Methylation of SLFN11 was significantly associated with tumor size (p < 0.05). SLFN11 suppressed gastric cancer growth both in vitro and in vivo and enhanced the ability of cisplatin to induce S-phrase arrest and apoptosis in gastric cancer cells. Conclusions: SLFN11 is frequently methylated in human gastric cancer, and its expression is regulated by promoter region methylation. Our results demonstrate that SLFN11 is a tumor suppressor in human gastric cancer, and methylation of SLFN11 may serve as a cisplatin resistant marker in human gastric cancer.

Original languageEnglish (US)
Pages (from-to)6124-6134
Number of pages11
JournalJournal of Cancer
Volume10
Issue number24
DOIs
StatePublished - 2019

Keywords

  • Cisplatin
  • DNA damage repair
  • Epigenetics
  • Gastric cancer
  • Methylation
  • SLFN11

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin'. Together they form a unique fingerprint.

Cite this